Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
06/2002
06/13/2002WO2002046190A2 Sulfonamido ether substituted imidazoquinolines
06/13/2002WO2002046189A2 Aryl ether substituted imidazoquinolines
06/13/2002WO2002046188A2 Amido ether substituted imidazoquinolines
06/13/2002WO2002046184A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
06/13/2002WO2002046183A2 Indazolyl-substituted pyrroline compounds as kinase inhibitors
06/13/2002WO2002046182A1 Semicarbazides and their uses as cyclin dependent kinase inhibitors
06/13/2002WO2002046171A2 Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
06/13/2002WO2002046170A2 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
06/13/2002WO2002046166A1 Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists
06/13/2002WO2002046158A2 Piperidine/piperazine-type inhibitors of p38 kinase
06/13/2002WO2002046152A2 Coniosetin and derivatives thereof, method for producing the same and use thereof
06/13/2002WO2002046148A1 Substituted anthranilic acids
06/13/2002WO2002046147A2 Perturbed membrane-binding compounds
06/13/2002WO2002045867A1 Method for producing a partial or complete active ingredient coating on and in implants and onplants
06/13/2002WO2002045750A1 Combination drugs
06/13/2002WO2002045749A2 Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
06/13/2002WO2002045746A2 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
06/13/2002WO2002045745A2 Methods and vaccines for providing in ovo protection against turkey rhinotracheitis
06/13/2002WO2002045743A2 Hcv vaccines
06/13/2002WO2002045742A2 Lipoteichoic acid immunogenic compositions and methods of making and using thereof
06/13/2002WO2002045741A2 Helicobacter pylori prime and boost vaccination comprising caga and nap antigens
06/13/2002WO2002045739A1 Immunomodulatory constructs and their uses
06/13/2002WO2002045728A1 Cosmetic and/or dermopharmaceutical preparations containing leaf extracts of the plant argania spinosa
06/13/2002WO2002045716A1 Use of pyrazolo[4,3-d]pyrimidines
06/13/2002WO2002045711A1 Use of anti-muscarinic agents and calcium channel blockers in combination
06/13/2002WO2002045706A2 The use of polymers for inactivating pathogens
06/13/2002WO2002045702A2 Tricyclic therapeutics for chemokine mediated diseases
06/13/2002WO2002045683A2 Reversible gelling system for ocular drug delivery
06/13/2002WO2002045661A1 Use of moulding compounds for producing treatment devices
06/13/2002WO2002045652A2 Tyrosine kinase inhibitors
06/13/2002WO2002045570A2 Methods and compositions for the diagnosis and treatment of viral disease using 55092
06/13/2002WO2002028270A3 The treatment of cancer utilizing a cox-2 inhibitor and a hmg-coa reductase inhibitor
06/13/2002WO2002024224A3 Use of replication-deficient poxvirus vector to boost cd4+ t cell immune response to antigen
06/13/2002WO2002022848A3 Compositions comprising mixtures of human cytokines and methods of producing the same
06/13/2002WO2002022130A3 Means for regulating immune defences
06/13/2002WO2002020554A3 Hiv peptides from conserved regions in gag p17 and 924 and their application in e.g. vaccines
06/13/2002WO2002018353A3 Oxazolidinone chemotherapeutic agents
06/13/2002WO2002017854A3 Cephalosporin antibiotics and prodrugs thereof
06/13/2002WO2002012245A3 Azabicyclic derivatives and their therapeutic use
06/13/2002WO2002011751A3 Combinations of dalfopristine/quinupristine with cefpirome
06/13/2002WO2002009746A3 Vaccines comprising outer membrane vesciles from gram negative bacteria
06/13/2002WO2002008418A3 Method of isolation of regulated virulence determinants from bacterial pathogens
06/13/2002WO2002008219A3 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
06/13/2002WO2002007712A3 Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs
06/13/2002WO2002004495A3 Streptococcus pyogenes antigen
06/13/2002WO2002004404A3 7,8 and 9-substituted tetracycline compounds
06/13/2002WO2002003998A3 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
06/13/2002WO2002000252A3 Non-human animal models of tolerance to hepatitis c virus immunogenes
06/13/2002WO2002000249A3 Multivalent vaccine composition
06/13/2002WO2001098297A3 A thiazine oxazolidinone
06/13/2002WO2001096377A3 Vaccine for congenital tremors in pigs
06/13/2002WO2001095884A3 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations
06/13/2002WO2001094415A3 Nuclear hormone receptor
06/13/2002WO2001093829A3 Powder compositions
06/13/2002WO2001091775A3 Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity
06/13/2002WO2001090159A3 Compositions and methods for delivery of a molecule into a cell
06/13/2002WO2001090104A3 -(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases
06/13/2002WO2001072277A3 Immunotherapeutic methods and compositions
06/13/2002WO2001059103A3 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
06/13/2002WO2001037819A3 Use of indirubine derivatives for making medicines
06/13/2002WO2001000199A9 Compounds obtained from salvia species having antiviral activity
06/13/2002WO2000066741A3 Conserved neisserial antigens
06/13/2002WO2000061736A9 Recombinant and mutant marek's disease virus
06/13/2002WO2000037610A3 Expression of immunogenic hepatitis b surface antigens in transgenic plants
06/13/2002WO2000037022A3 Combination therapy for the treatment of sepsis
06/13/2002US20020072630 Therapy
06/13/2002US20020072609 Process for preparing arylacetylaminothiazoles
06/13/2002US20020072596 Nucleotide sequences coding transrerrins; for use in the treatment of nervous system., blood abbd anemia, heme biosynthesis disorders
06/13/2002US20020072595 Nucleic acid for use in kits for detection of preferential bacterial infection
06/13/2002US20020072528 Are immunomodulators and induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor, and inhibit T-helper-type 2 immune response; useful for therapy of viral and neoplastic diseases
06/13/2002US20020072523 For therapy of inflammatory and immune diseases
06/13/2002US20020072518 Bicyclic alphavbeta3 antagonists
06/13/2002US20020072513 Process for the production of clavulanic acid salts
06/13/2002US20020072510 3-nitrogen-6,7-dioxygen steroids and uses related thereto
06/13/2002US20020072504 Method and reagents for genetic immunization
06/13/2002US20020072500 3-(carboxy(hydroxy)alkylaminocarbonylmethylaminocarbonyl), 5-(tetrahydropyrimidin-2-yl-amino)phenol for example
06/13/2002US20020072485 Administering prior to the impairment of glucose and/or oxygen to the brain an NMDA receptor subunit (NR2B) selective NMDA antagonist to inhibit neuronal damage (ischemia)
06/13/2002US20020072480 Water-soluble, chlorhexidine-containing compositions and use thereof
06/13/2002US20020072090 Hr-1 receptor
06/13/2002US20020072062 Generating clne containing chloramphenicol gene cluster; obtain microgranism, extract genome, form library, transform cells, screen clones for chloramphenicol expression
06/13/2002US20020072051 Detecting modulators of fungal activity; obtain yeast cell, incubate with modulator, detect expression reporter molecules
06/13/2002US20020071863 Sustained release oral dosage form that is free of in-situ aggregation effect of the antiviral drug and provides substantially improved bioavailability of said antiviral drug.
06/13/2002US20020071851 Borrelia burgdorferi bacterin
06/13/2002US20020071849 A41L protein or a chemokine-binding fragment thereof; detecting an interaction of the chemokine-binding molecule with a chemokine; antiinflammatory agents
06/13/2002US20020071848 Inactivated influenza virus and a purified recombinant envelope protein from the virus, or a fragment or precursor thereof.
06/13/2002US20020071843 Targeted therapeutic agents
06/13/2002US20020071835 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
06/13/2002US20020071822 Polymer comprising a backbone comprising ester, thioester, or amide linkages, and wherein the backbone comprises one or more groups that will yield a biologically active compound upon hydrolysis of the polymer.
06/13/2002DE10061574A1 Blockierung der Anlagerung von Keimen bei Vögeln Blocking the attachment of germs in birds
06/13/2002CA2436984A1 Urea substituted imidazoquinoline ethers
06/13/2002CA2436983A1 Sulfonamido ether substituted imidazoquinolines
06/13/2002CA2436916A1 Use of pyrazolo[4,3-d]pyrimidines
06/13/2002CA2436870A1 Substituted anthranilic acids
06/13/2002CA2436856A1 Immunomodulatory constructs and their uses
06/13/2002CA2436732A1 Protein modification and maintenance molecules
06/13/2002CA2436601A1 Perturbed membrane-binding compounds
06/13/2002CA2431187A1 Macroheterocylic compounds useful as kinase inhibitors
06/13/2002CA2431166A1 Indazolyl-substituted pyrroline compounds as kinase inhibitors
06/13/2002CA2431151A1 Heterocyclic ether substituted imidazoquinolines
06/13/2002CA2431040A1 Substituted imidazopyridines
1 ... 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 ... 1798